Zepbound is the brand name for tirzepatide, a once-weekly injectable medication that acts as a dual GLP-1 and GIP receptor agonist. The Food and Drug Administration approved Zepbound in 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related health condition. In December 2024, the FDA also approved Zepbound as the first medication indicated for moderate-to-severe obstructive sleep apnea in adults with obesity. The same active molecule, tirzepatide, is sold under the brand name Mounjaro for type 2 diabetes, but Zepbound is specifically the version marketed for weight management and sleep apnea. Patients typically inject Zepbound weekly using a prefilled pen under a doctor’s guidance.
Families in addiction recovery sometimes ask about Zepbound because incretin hormones like GLP-1 and GIP interact with the same brain reward circuitry involved in cravings and compulsive use. Early research suggests that activating these receptors may dampen dopamine driven urges, which has sparked interest in whether tirzepatide could someday support recovery from alcohol or substance use disorders. It is important to understand that this application remains investigational. Zepbound is not FDA-approved for addiction treatment, and any such use would be off-label and require careful medical supervision. At Carrara Treatment, medication questions like these are addressed by our clinical team as part of a broader, individualized recovery plan, never as a stand-alone solution.
How Does Zepbound Work In The Body?
Tirzepatide, the active ingredient in Zepbound, mimics two natural gut hormones called GLP-1 and GIP. Together these incretin hormones slow digestion, increase feelings of fullness, and help regulate blood sugar, which is why the medication supports meaningful weight loss in clinical trials. Zepbound is delivered as a once-weekly subcutaneous injection, and doses are increased gradually to help the body adjust.
Beyond weight, the same hormonal pathways influence breathing and airway tone during sleep, which is the basis for the sleep apnea approval. The most common side effects are gastrointestinal, including nausea, diarrhea, constipation, and decreased appetite, and these tend to be strongest during dose increases. Anyone considering Zepbound should be evaluated by a physician who understands their full medical and psychiatric history.
Could Zepbound Play A Role In Addiction Recovery?
Scientists have long known that GLP-1 receptors sit within the mesolimbic dopamine system, the same brain network that drives craving and reward in addiction. This has led researchers to test whether incretin based medications can quiet the urge to drink or use drugs. For tirzepatide specifically, the evidence is still early: a handful of preclinical animal studies and some observational human data hint that it may reduce alcohol consumption, but there are no completed randomized controlled trials establishing tirzepatide as an addiction treatment.
By comparison, semaglutide has a larger, though still developing, body of human research in this area. Because Zepbound carries no FDA approval for substance use disorders, any use for that purpose would be off-label and should only happen under close medical supervision, alongside evidence-based therapies like counseling, peer support, and structured rehab programming rather than in place of them.
Frequently Asked Questions
What is Zepbound approved to treat?
Zepbound is FDA-approved for two conditions: chronic weight management in adults with obesity, or with overweight and a weight-related condition such as high blood pressure, and moderate-to-severe obstructive sleep apnea in adults with obesity. The weight management approval came in 2023, and the sleep apnea approval followed in December 2024, making Zepbound the first medication cleared specifically for that breathing disorder. It is not approved for diabetes or for any substance use disorder.
Is Zepbound the same medication as Mounjaro?
Yes, in terms of active ingredient. Both Zepbound and Mounjaro contain tirzepatide, a dual GLP-1 and GIP receptor agonist made by the same manufacturer. Mounjaro is approved for managing type 2 diabetes, while Zepbound is approved for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Dosing schedules and packaging differ, but patients should never substitute one brand for the other without a prescriber’s explicit guidance.
Can Zepbound help treat alcohol or drug addiction?
Not officially. Zepbound is not FDA-approved for treating alcohol or substance use disorders, and using it for that purpose would be off-label. Researchers are interested because GLP-1 and GIP receptors sit within brain reward circuits linked to craving, and early animal studies plus limited observational data suggest possible reductions in alcohol use. No completed randomized trials confirm this benefit for tirzepatide. Anyone exploring this option should talk with a treatment team.
